Adjuvant Therapy of Primary Breast Cancer: Closing Summary
Adjuvant therapy for stage I and II breast cancer remains in evolution as new data emerge from controlled randomized trials and from the overview analysis by the Early Breast Cancer Trialists’ Collaborative Group  (reprinted in part in this volume; referred to below as the Overview). The Fourth International Conference on Adjuvant Therapy of Primary Breast Cancer, held in St. Gallen, Switzerland, in February, 1992, brought together breast cancer experts from all over the world to present their most recent data and to discuss the remaining challenges that confront both clinicians and basic scientists.
KeywordsPlacebo Toxicity Europe Estrogen Oncol
Unable to display preview. Download preview PDF.
- 4.Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75 000 women. Lancet 339:1–5, 71–85Google Scholar
- 5.Fisher B (1992) The recent NSABP experience and strategies. Proceedings of the 4th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. GallenGoogle Scholar
- 7.National Cancer Institute (1988) Clinical alert. National Cancer Institute, BethesdaGoogle Scholar